Dara Holder

Phase II Trial of Intravesical Nanoparticle Albumin Bound Paclitaxel for the Treatment of Nonmuscle Invasive Urothelial Carcinoma of the Bladder after bacillus Calmette-Guérin Treatment Failure

James M. McKiernan, Dara Holder, Rashed Ghandour et al. · The Journal of Urology · 2014 · 84 citations

A Phase I Trial of Intravesical Cabazitaxel, Gemcitabine and Cisplatin for the Treatment of Nonmuscle Invasive bacillus Calmette-Guérin Unresponsive or Recurrent/Relapsing Urothelial Carcinoma of the Bladder

G. Joel DeCastro, Wilson Sui, Jamie S. Pak et al. · The Journal of Urology · 2020 · 48 citations · Full text

High Expression of the PAX3-FKHR Oncoprotein Is Required to Promote Tumorigenesis of Human Myoblasts

Shujuan J. Xia, Dara Holder, Bruce Pawel et al. · American Journal Of Pathology · 2009 · 46 citations · Full text

Cancer Research, Cell Regulation, Oncogenic Agent +11

Neoadjuvant chemotherapy in the treatment of muscle invasive bladder cancer with mixed histology.

James Lin, Michael J. Whalen, Dara Holder et al. · PubMed · 2013 · 14 citations

A phase I trial for the use of intravesical cabazitaxel, gemcitabine, and cisplatin (CGC) in the treatment of BCG-refractory nonmuscle invasive urothelial carcinoma of the bladder.

G. Joel DeCastro, Wilson Sui, Jamie S. Pak et al. · Journal of Clinical Oncology · 2017 · 11 citations

Surgical Oncology, Surgery, Pharmacotherapy +17